Biotech News

OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026

Bio-Reference Laboratories (BRLI)Bio-Reference Laboratories2026-07-23 16:30 ESTEarnings

MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today announced that it will report operating and financial results for the second-quarter 2026 on Monday, July 27, 2026. OPKO’s senior management will host a conference call and webcast at 4:30 p.m. ET to provide a business update, discuss results and financial guidance.

CONFERENCE CALL & WEBCAST INFORMATION

OPKO encourages participants to pre-register for the conference call using this link . Participants who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the call start time. Those unable to pre-register may participate by dialing 833-630-0584 (U.S.) or 412-317-1815 (International). A webcast of the call can also be accessed through OPKO’s Investor Relations here .

A telephone replay will be available until August 3, 2026, by dialing 855-669-9658 (U.S.) or 412-317-0088 (International) and providing the passcode 6858214. A webcast replay will be available beginning approximately one hour after the completion of the live conference call through OPKO’s Investor Relations here .

About OPKO Health

OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com .

Contacts:

Alliance Advisors IR Vivian Cervantes, 973-873-7724 [email protected]

Source: OPKO Health, Inc. Released July 23, 2026

Open original release

Related news

BRLIBio-Reference Laboratories2026-06-15 12:00 EST

Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026

BRLIBio-Reference Laboratories2026-04-30 12:30 EST

OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China

BRLIBio-Reference Laboratories2026-04-28 20:05 EST

OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results

BRLIBio-Reference Laboratories2026-04-22 12:00 EST

OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas

BRLIBio-Reference Laboratories2026-04-21 20:05 EST

OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026

BRKRBruker2026-07-24 20:01 EST

Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast

NAMSNewAmsterdam Pharma2026-07-24 12:00 EST

NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

IMVTImmunovant2026-07-23 20:05 EST

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

EHCEncompass Health Corporation2026-07-23 12:00 EST

Encompass Health increases and declares dividend on common stock

IKTInhibikase Therapeutics2026-07-23 12:00 EST

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

Bio-Reference Laboratories

Bio-Reference Laboratories is a clinical laboratory and diagnostic services company focused on testing and related healthcare services. Its role is to process and interpret lab work rather than develop therapeutics.

Recent company news

Stock data

Close
Market cap
Exchange
NASDAQ
Sector
MedTech
Location
United States